NCT05876949View on ClinicalTrials.gov

AVT03 With Xgeva in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions
This is a Phase I Study Conducted in Healthy Volunteers
Interventions
BIOLOGICAL

AVT03

AVT03 will be given as 1 time subcutaneous injection

BIOLOGICAL

Denosumab

Xgeva (denosumab) will be given as 1 time subcutaneous injection

Trial Locations (3)

Unknown

Biokinetica, Józefów

Farmovs, Bloemfontein

Richmond Pharmacology, London

All Listed Sponsors
lead

Alvotech Swiss AG

INDUSTRY